Nonclinical Toxicology for Oncology IND Submissions
Many oncology programs still treat toxicology as a box-checking exercise for IND submission. That mindset creates risk. Regulators do not expect clean data. They expect a clear, defensible story for how toxicity informs safe clinical entry.
This white paper challenges the assumption that toxicity findings slow development. Analysis from 60 small-molecule oncology programs shows the opposite. Predictable findings across the lymphoid, gastrointestinal, hematologic, and liver systems consistently supported IND approval when properly interpreted.
The real risk is not toxicity. It is a weak translation of nonclinical data into dose rationale, monitoring strategy, and investigator guidance.
This resource shows how to:
- Turn expected toxicities into a regulatory advantage
- Strengthen first-in-patient dose justification
- Translate findings into actionable clinical plans
- Address species differences and study design decisions with confidence
Download the paper to rethink how your toxicology package can accelerate IND readiness and strengthen regulatory confidence.